Tezspire hits key endpoints in Phase III eosinophilic esophagitis trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. SMCI
8. RTX
9. S
10. COF

Go back to Tezspire hits key endpoints in Phase III eosinophilic esophagitis trial

TEZSPIRE positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission presented at United European Gastroenterology Wee

October 20, 2026 9:00 AM EDT

First and only biologic therapy to achieve statistically significant and clinically meaningful histologic remission and symptom improvements at week 24 that were sustained through week 52 vs. placebo

TEZSPIRE attained statistically significant total endoscopic remission with visible clearance of inflammation and fibrosis,... More